View Cart  

GSK Begins Late-Stage Mepolizumab Trials in Severe Asthma

A A
GlaxoSmithKline (GSK) is moving its biologic mepolizumab forward, beginning two Phase III trials of the drug as an adjunct therapy in severe uncontrolled refractory asthma.

To View This Article:

Login

Subscribe To Drug Industry Daily